Tricalcium phosphates, their composites, implants incorporating them, and methods for their production
View Patent ↗Methods for the synthesis of tricalcium phosphates are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the tricalcium phosphate precursor precipitate. Particulate tricalcium phosphate compositions having an average crystal size of about 250 nm or less are provided. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants.
1. An article comprising a porous consolidated TCP structure,
wherein the TCP structure comprises TCP crystals having an average crystal size of about 1 μm or less and an aspect ratio of about 3:1 or more,
wherein the TCP structure has a porosity of about 20% or greater, and
wherein the article has a dimension of about 0.5 cm or greater, a compressive strength of about 50 MPa or greater, and a three point bending strength of about 20 MPa or greater.
2. The article of claim 1 , wherein the TCP structure has a porosity of about 40% or greater.
3. The article of claim 1 , wherein the TCP structure has an average pore size of about 300 μm or less.
4. The article of claim 1 , wherein the TCP structure has a compressive strength of about 100 MPa or greater.
5. The article of claim 1 , wherein the TCP structure has an average crystal size of about 500 nm or less.
6. The article of claim 1 , wherein the TCP structure comprises α-TCP, β-TCP, or a combination thereof.
7. The article of claim 1 , wherein the article has a dimension of about 1 cm or greater.
8. The article of claim 1 , wherein the article is a prosthesis.
9. The article of claim 1 , wherein the article is at least part of a prosthesis.
10. The article of claim 1 , wherein the article comprises an exterior coating on a prosthesis.
11. The article of claim 1 , wherein the article is a bioactive implant.
12. The article of claim 11 , wherein the bioactive implant is an orthopedic or dental implant.
13. The article of claim 1 , wherein the TCP structure comprises a secondary additive.
14. The article of claim 13 , wherein the secondary additive is an organic additive.
15. The article of claim 13 , wherein the secondary additive is a polymeric additive.
16. The article of claim 15 , wherein the polymeric additive is selected from the group consisting of polylactic acid, polyglycolic acid, polylactic/polyglycolic acid copolymers, polypropylenefumarate, polyhydroxybutyric acid, polyhydroxyvalerie acid, polycaprolactone, polyhydroxycarboxylic acids, polybutyrene succinate, polybutylene adipate, collagen, chitosan, alginate, celluloses, starches, sugars, polypeptides, polyethylene glycols, vinyl pyrrolidones, acrylamides, methaerylates, copolymer micelles, and combinations thereof.
17. The article of claim 13 , wherein the secondary additive is a biological additive.
18. The article of claim 17 , wherein the biological additive is selected from the group consisting of plasmid DNA, RNA, proteins, bone morphogenetic proteins, and combinations thereof.
19. The article of claim 13 , wherein the secondary additive is a pharmaceutical additive.
20. The article of claim 19 , wherein the pharmaceutical additive is selected from the group consisting of bisphosphonates, cis-platinum compounds, antibiotics, anti-inflammatory agents, anti-arthritism agents, erythropoeitin, and combinations thereof.
21. The article of claim 13 , wherein the secondary additive is hydroxyapatite.
22. The article of claim 13 , wherein the secondary additive is added in an amount of between about 1% and about 50% by volume.
23. The article of claim 1 , wherein the TCP structure has a macroporosity and a nanoporosity.
24. The article of claim 1 , wherein the TCP structure has an interconnected porosity.
25. The article of claim 1 , wherein the article has a resorption time of about 1 month or more.